Skip to content
Politically.com Search all
Menu

Proposed rule 2026-14073

Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments

The Food and Drug Administration (FDA, the Agency, or we) is proposing to amend the drug establishment registration and drug listing requirements with respect to establishments engaged in distributed manufacturing and foreign drug establishments. This action, if finalized, will provide a pathway for a distributed manufacturing establishment that manufactures drugs at multiple different physical locations to register as a single drug manufacturing establishment and align drug establishment registration and drug listing regulations applicable to foreign drug establishments with statutory changes made by the Preparing for and Responding to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act).

Source: FederalRegister.gov API v1Recently refreshed. Last successful refresh: 2026-07-31 22:49:02 UTC.

Source-supplied record

Document details

Document number
2026-14073
Published
Jul 13, 2026
Effective
Not supplied
Comments close
Sep 11, 2026 (open)
Federal Register citation
91 FR 42888

Docket identifiers

  • Docket No. FDA-2025-N-6075

CFR references

  • Title 21, part 207